Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.

@article{Lairson2014CostutilityAO,
  title={Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.},
  author={David R. Lairson and Rohan C Parikh and Janice N. Cormier and Xianglin L. Du},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2014},
  volume={17 1},
  pages={34-42}
}
OBJECTIVES Most economic evaluations of chemotherapies for ovarian cancer patients have used hypothetical cohorts or randomized control trials, but evidence integrating real-world survival, cost, and utility data is limited. METHODS A propensity score-matched cohort of 6856 elderly (≥65 years) ovarian cancer patients diagnosed from 1991 to 2005 from the Surveillance, Epidemiology, and End Results-Medicare data cohort were included. Treatment regimens (i.e., no chemotherapy, platinum-based… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS